H.R. 44 (119th)Bill Overview

Rural 340B Access Act of 2025

Health|HealthHealth care costs and insurance
Cosponsors
Support
Republican
Introduced
Jan 3, 2025
Discussions
Bill Text
Current stageCommittee

Referred to the House Committee on Energy and Commerce.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

This bill amends section 340B(a)(4) of the Public Health Service Act to add rural emergency hospitals to the definition of covered entities eligible for the 340B drug discount program. It specifies eligible ownership types: state or local government-owned, public or private non‑profit granted governmental powers, or private non‑profit with a contract to provide care to low‑income individuals not eligible for Medicare or Medicaid.

Why people may split

Liberals emphasize improved rural access and equity benefits

Watch point

Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and accountability detail.

This bill amends section 340B(a)(4) of the Public Health Service Act to add rural emergency hospitals to the definition of covered entities eligible for the 340B drug discount program.

It specifies eligible ownership types: state or local government-owned, public or private non‑profit granted governmental powers, or private non‑profit with a contract to provide care to low‑income individuals not eligible for Medicare or Medicaid.

Passage40/100

Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufacturers.

CredibilityAligned

Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and accountability detail.

Contention55/100

Liberals emphasize improved rural access and equity benefits

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Likely helpedManufacturers

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Potential benefitIncreases access to discounted outpatient drugs for rural patients served by rural emergency hospitals.
  • Potential benefitLowers pharmacy acquisition costs for eligible REHs, potentially improving hospital financial margins.
  • Potential benefitMay reduce out-of-pocket prescription costs for low-income rural patients served by these hospitals.
Likely burdened
  • ManufacturersExpands manufacturer discounts, potentially shifting costs to other purchasers or contributing to higher list prices.
  • ManufacturersMay increase administrative and compliance burden for HRSA, manufacturers, and participating hospitals.
  • Potential burdenCould heighten program integrity risks like diversion or duplicate discounts absent strengthened oversight.
03 · Why people split

Why the argument around this bill splits.

Liberals emphasize improved rural access and equity benefits
Progressive90%

Likely sees the bill as a targeted expansion of an existing program to strengthen rural health care capacity and lower drug costs for vulnerable patients.

Views it as consistent with improving access and equity for low‑income rural populations, though wants safeguards against misuse.

Leans supportive
Centrist70%

Generally supportive of expanding access to rural care but cautious about implementation details and budgetary effects.

Sees value in helping rural hospitals, but wants clear accountability, fiscal estimates, and guardrails against unintended incentives.

Leans supportive
Conservative40%

Mixed view: welcomes measures that preserve rural hospitals, but skeptical about expanding federal program eligibility and its downstream effects.

Concerned about expanding entitlements, regulatory complexity, and costs to private sector drug manufacturers.

Split reaction
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood40/100

Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufacturers.

Scope and complexity
24%
Scopenarrow
24%
Complexitylow
Why this could stall
  • No official cost or CMS implementation estimate included
  • Intensity of pharmaceutical industry lobbying and litigation threat
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Liberals emphasize improved rural access and equity benefits

Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufactu…

Unlocked analysis

Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and account…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis